BRIEF published on 10/14/2025 at 07:05, 10 months 29 days ago Innate Pharma met en avant lacutamab lors d'un événement analystes et investisseurs Investisseurs Essai Clinique Innate Pharma Lacutamab Syndrome De Sézary
PRESS RELEASE published on 10/14/2025 at 07:00, 10 months 29 days ago Informations privilégiées / Autres communiqués Innate Pharma organise un événement analystes et investisseurs dédié à Lacutamab le 28 octobre 2025, mettant en lumière les perspectives cliniques et commerciales du produit Investisseurs Événement Innate Pharma Analystes Lacutamab
PRESS RELEASE published on 10/14/2025 at 07:00, 10 months 29 days ago Inside Information / Other news releases Innate Pharma to host analyst and investor event on Lacutamab on October 28, 2025. Event includes clinical perspectives, market outlook, and updates on Phase 3 trial and regulatory pathway for lacutamab Phase 3 Trial Investor Event Regulatory Pathway Innate Pharma Lacutamab
PRESS RELEASE published on 09/22/2025 at 13:41, 11 months 20 days ago Informations privilégiées / Communiqué sur comptes, résultats
PRESS RELEASE published on 09/17/2025 at 07:00, 11 months 25 days ago Informations privilégiées / Communiqué sur comptes, résultats
BRIEF published on 09/10/2025 at 10:35, 1 year ago Innate Pharma Annonce une Conférence Téléphonique pour ses Résultats Semestriels 2025 Résultats Financiers Immunothérapie Conférence Téléphonique Partenariats Biopharmaceutiques Innate Pharma
BRIEF published on 09/10/2025 at 10:35, 1 year ago Innate Pharma Announces 2025 Half-Year Results Conference Call Financial Results Conference Call Immunotherapy Innate Pharma Biopharmaceutical Partnerships
PRESS RELEASE published on 09/10/2025 at 10:30, 1 year ago Inside Information / Other news releases Innate Pharma schedules conference call and webcast for first half 2025 financial results and business update. Details for participation available on the company's website Financial Results Conference Call Business Update Webcast Innate Pharma
PRESS RELEASE published on 09/10/2025 at 10:30, 1 year ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique pour présenter ses résultats financiers et l’avancée de son portefeuille au premier semestre 2025 Résultats Financiers Conférence Téléphonique Portefeuille Innate Pharma Biotechnologies
BRIEF published on 09/02/2025 at 07:05, 1 year ago Innate Pharma : Mise à jour sur le capital et les droits de vote Droits De Vote Actions AMF Immobilier Innate Pharma
Published on 09/12/2026 at 02:35, 11 hours 49 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 24 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 19 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 59 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 24 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 54 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 9 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 14 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 40 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 9 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
